Table 2.
Treatment-emergent AEs occurring in ≥10% of patients in either ADT group (safety sample)
| AE, % | Bupropion plus aripiprazole (n = 46) | SSRI/SNRI plus aripiprazole (n = 242) |
|---|---|---|
| Fatigue |
26.1 |
23.6 |
| Somnolence |
21.7 |
18.2 |
| Akathisia |
17.4 |
23.6 |
| Headache |
17.4 |
15.3 |
| Increased appetite |
15.2 |
11.2 |
| Insomnia |
15.2 |
15.7 |
| Arthralgia |
13.0 |
3.3 |
| Irritability |
13.0 |
3.7 |
| Middle insomnia |
13.0 |
2.5 |
| Upper respiratory tract infection |
13.0 |
10.7 |
| Erectile dysfunction |
12.5 |
2.6 |
| Anxiety |
10.9 |
11.2 |
| Asthenia |
10.9 |
3.7 |
| Back pain |
10.9 |
5.4 |
| Dry mouth |
10.9 |
10.3 |
| Nausea |
10.9 |
11.6 |
| Restlessness |
10.9 |
12.4 |
| Salivary hypersecretion |
10.9 |
3.7 |
| Tremor |
10.9 |
8.7 |
| Dizziness |
8.7 |
10.3 |
| Weight increased | 8.7 | 19.0 |
ADT, antidepressant treatment; AE, adverse event; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.